Congressman charged in biotech insider trading case
December 26, 2018 Collins was a member of Innate’s board of directors and held a 17% stake in the biotech. According to prosecutors, Collins learned from Innate’s CEO trial had failed on June 22. Collins replied, “Wow. Makes no sense. How are these results even possible???” before calling his son, Cameron. Prosecutors think Collins told … Read more